Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Summary

This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.

Timeline

Start

2024-01-10

Primary completion

2026-11-30

Completion

2027-11-30

Drugs

Indications